Curcumin Triggers Ferroptosis in Thyroid Cancer via GPX4 Downregulation (2026 Study)
A 2026 preclinical study shows curcumin induces ferroptosis in papillary thyroid cancer cells by downregulating GPX4, suppressing tumour growth in mice without organ toxicity.
By Sanare Lab · August 6, 2026 · 5 min read
A new 2026 laboratory study (Journal of Molecular Histology) shows that curcumin suppresses papillary thyroid cancer cells by triggering ferroptosis — a form of iron-dependent cell death — through downregulation of the GPX4 protein. In vivo xenograft experiments confirmed tumour growth inhibition without observable organ toxicity.
Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy, and while most cases respond well to surgery and radioiodine, a subset of tumours becomes resistant to standard treatment. Researchers at Bengbu Medical University (China) have now published preclinical evidence that curcumin — the active polyphenol in turmeric — can kill PTC cells through a mechanism called ferroptosis, distinct from classical apoptosis.
The study, published in the Journal of Molecular Histology (August 2026), examined 54 human PTC tissue samples and found that elevated GPX4 (glutathione peroxidase 4) expression correlated with worse prognosis, including higher rates of lymph node metastasis and shorter progression-free survival. GPX4 is a key enzyme that protects cells from ferroptosis by neutralising lipid peroxides — making it an attractive therapeutic target.
In cell culture experiments using B-CPAP papillary thyroid cancer cells, curcumin treatment downregulated GPX4, increased markers of lipid peroxidation (MDA, ROS, Fe²⁺), and decreased glutathione (GSH) — the hallmarks of ferroptosis. When researchers added ferrostatin-1 (a ferroptosis inhibitor), curcumin's anti-cancer effects were partially reversed, confirming that ferroptosis is the primary mechanism. A nude mouse xenograft model showed significant tumour growth suppression with no observable organ toxicity.
Study Overview
The study was conducted by researchers from the School of Clinical Medicine and the Department of Nuclear Medicine at Bengbu Medical University, China, and published in the Journal of Molecular Histology on 4 August 2026 (DOI: 10.1007/s10735-026-10922-z). It combined tissue analysis from 54 PTC patients, in vitro cell experiments, and an in vivo xenograft mouse model.
| Parameter | Detail |
|---|---|
| Study type | Preclinical (in vitro + in vivo) |
| Cancer type | Papillary thyroid carcinoma (PTC) |
| Cell line | B-CPAP (human PTC cells) |
| In vivo model | Nude mouse xenograft |
| Human tissue samples | 54 PTC tissue specimens |
| Key target | GPX4 (glutathione peroxidase 4) |
| Mechanism | Ferroptosis via GPX4 downregulation |
| Published | August 4, 2026 — Journal of Molecular Histology |
What Is Ferroptosis?
Ferroptosis is a form of regulated cell death driven by iron-dependent accumulation of lipid peroxides. Unlike apoptosis (the classical "programmed" cell death pathway), ferroptosis is triggered when the cell's antioxidant defences — particularly the GPX4 enzyme — are overwhelmed or inhibited. Cancer cells that have developed resistance to apoptosis-inducing drugs may still be vulnerable to ferroptosis, making it a promising alternative therapeutic strategy.
GPX4 converts toxic lipid hydroperoxides into harmless lipid alcohols. When GPX4 is inhibited or downregulated, lipid peroxides accumulate, damaging cell membranes and ultimately killing the cell. The study found that elevated GPX4 in PTC tissue was associated with worse clinical outcomes, suggesting that PTC cells may rely on GPX4 to survive — and that targeting it with curcumin could be therapeutically relevant.
Key Findings
The researchers reported the following results:
- GPX4 overexpression in PTC tissue correlated with lymph node metastasis, distant metastasis, and reduced progression-free survival in 54 patient samples.
- Curcumin downregulated GPX4 in B-CPAP cells and induced ferroptotic markers: increased malondialdehyde (MDA), reactive oxygen species (ROS), and Fe²⁺; decreased glutathione (GSH).
- Ferroptosis inhibitor ferrostatin-1 (Fer-1) reversed curcumin-induced cell death and partially restored migration, confirming ferroptosis as the primary mechanism.
- GPX4 overexpression partially rescued curcumin-induced loss of cell viability and lipid peroxidation, further supporting the GPX4-ferroptosis axis.
- In vivo: curcumin significantly suppressed tumour growth in the xenograft model without observable organ toxicity.
- Molecular docking suggested a possible interaction between curcumin and GPX4 at the Gln-55 and Pro-155 residues — though the authors note this was not experimentally validated in the current study.
Evidence Level and Limitations
This is a preclinical study — it demonstrates a promising mechanism in cell culture and mouse models, but has not been tested in humans. Key limitations include:
- No clinical trial data; results in human patients may differ significantly.
- The molecular docking finding (curcumin binding to GPX4) is a computational prediction, not yet confirmed by structural biology experiments.
- Curcumin has notoriously poor oral bioavailability; the concentrations used in cell culture may not be achievable in human thyroid tissue without specialised delivery systems.
- The study used a single PTC cell line (B-CPAP); results may not generalise to all PTC subtypes.
Overall evidence level: Promising preclinical signal — not yet evidence of clinical benefit in thyroid cancer patients.
For background, see our guide to what the curcumin and cancer research shows.
Plan the numbers in our interactive dosing workspace.
Frequently Asked Questions
What is GPX4 and why does it matter in cancer?
GPX4 (glutathione peroxidase 4) is an enzyme that protects cells from ferroptosis by neutralising lipid peroxides. Many cancer cells overexpress GPX4 to evade this form of cell death. In this study, high GPX4 in papillary thyroid cancer tissue was linked to worse prognosis, suggesting cancer cells depend on it for survival.
Does this mean curcumin treats thyroid cancer?
No. This is a preclinical study in cell lines and mice. While the results are scientifically interesting, there are no human clinical trials demonstrating that curcumin treats papillary thyroid carcinoma. Patients should not alter their treatment plans based on this research.
What is ferroptosis and how is it different from apoptosis?
Ferroptosis is a form of cell death driven by iron-dependent lipid peroxidation, distinct from apoptosis (classical programmed cell death). Cancer cells resistant to apoptosis-inducing drugs may still be vulnerable to ferroptosis, which is why researchers are exploring it as an alternative anticancer strategy.
Is curcumin bioavailable enough to reach thyroid tissue?
Standard curcumin has poor oral bioavailability — most is metabolised before reaching target tissues. The concentrations used in this cell study may not be achievable in human thyroid tissue with conventional curcumin supplements. Nanoformulations and phospholipid complexes are being studied to improve delivery.
A 2026 preclinical study from Bengbu Medical University in China found that curcumin, the active compound in turmeric, killed papillary thyroid carcinoma cells in the lab by lowering glutathione peroxidase 4, a protein that helps cells avoid ferroptosis (iron-dependent cell death). In 54 human tumor samples, higher glutathione peroxidase 4 was linked with worse outcomes. Curcumin also slowed tumor growth in a mouse model with no observable organ toxicity, but this has not been tested in humans as a thyroid cancer treatment.
Shop Sanare Lab
Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.
120 capsules — with Black Pepper for absorption
Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.
References
- Ren L, Ding H, Sun Y, et al. Ferroptosis induction by curcumin through regulating the expression of glutathione peroxidase 4 in papillary thyroid carcinoma. J Mol Histol. 2026 Aug 4;57(4):257. DOI: 10.1007/s10735-026-10922-z. PMID: 42550316.
Medical Disclaimer
This article is for educational and informational purposes only and does not constitute medical advice. The research described is preclinical and has not been validated in human clinical trials. Do not use this information to make decisions about cancer treatment. Always consult a qualified healthcare professional before making any changes to your treatment plan.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.